Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;35(Suppl 3):549-556.
doi: 10.31138/mjr.290124.dtt. eCollection 2024 Dec.

Difficult-to-Treat Spondyloarthritis in Morocco: A Real-World Study

Salma Zemrani  1 , Bouchra Amine  1 , Imane ElBinoune  1 , Samira Rostom  1 , Rachid Bahiri  1
Affiliations

Difficult-to-Treat Spondyloarthritis in Morocco: A Real-World Study

Salma Zemrani et al. Mediterr J Rheumatol. .

Abstract

Objectives: High biologic requirement in inflammatory rheumatic diseases (IRD) may indicate a difficult to treat (D2T) condition. In axial spondyloarthritis (axSpA), a consensual definition for this concept is still lacking. Our objectives are to identify the prevalence and characteristics of multiswitcher patients with axSpA, and to analyse the number and reasons for switches.

Methods: This is a longitudinal observational study including patients treated with biologic agents for axSpA. We propose to define D2T patients as those who required more than 2 b/tsDMARD. Patients who did not fulfil this definition were used as controls. The prevalence of multiswitchers was calculated, and characteristics were compared between the two groups. The number and reasons for switches were analysed in the D2T group.

Results: 124 patients were included. The prevalence of multiswitchers was 24.19%. There were no significant differences between the two groups in the age, sex, and comorbidities. D2T patients have more arthritis (p=0.01), and fibromyalgia (p=0.04), and higher disease activity before initiating biotherapy, (BASDAI:p=0.04), (ASDAS:p=0.04). Additionally, the time from diagnosis to the first use of biologic was longer (p=0.04). In the multivariate analysis, the D2T condition was found to be associated with fibromyalgia (p=0.01). Among this group, the prevalence of those treated with 3, 4, and 5 b/tsDMARD was 86%, 9%, and 5%, respectively, the primary and secondary failures were the most common reasons for switching.

Conclusion: We suggest that D2T-axSpA present several characteristics. Identification of this category in large studies is necessary to establish a consensus definition.

Keywords: axial spondyloarthritis; biological therapy; difficult-to-treat.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1.
Figure 1.
Number of switches in D2T group.
Figure 2.
Figure 2.
Biologics type requirements during different switches in D2T group. ADA: Adalimumab; IFX: Infliximab; ETN: Etanercept; GOLI: Golimumab; CERTO: Certolizumab; SEC: Secukinumab.
Figure 3.
Figure 3.
Reasons for switch in D2T group.
See this image and copyright information in PMC

References

    1. Ryu W, Tadashi O, Takaho G, Naofumi Y, Kazuo F, Shinsuke Y, et al. Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems. Front Med 2022;9:1049875. - PMC - PubMed
    1. Nagy G, Roodenrijs N, Welsing P MJ, Kedves M, Hamar A, van der Goes MC, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 2021;80:31–5. - PMC - PubMed
    1. Nagy G, Roodenrijs N, Welsing P MJ, Kedves M, Hamar A, van der Goes MC, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 2021;8:20–33. - PMC - PubMed
    1. Wendling D, Verhoeven F, Prati C. Is the Difficult-to-Treat (D2T) concept applicable to axial spondyloarthritis? Joint Bone Spine 2023;90:105512. - PubMed
    1. Taitt HA, Balakrishnan R. Spondyloarthritides. Emerg Med Clin North Am 2021;40:159–78. - PubMed